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Abstract
Background: the long-term effect of the use of drugs with anticholinergic activity on cognitive function remains unclear.
Methods: we conducted a systematic review and meta-analysis of the relationship between anticholinergic drugs and risk of
dementia, mild cognitive impairment (MCI) and cognitive decline in the older population. We identified studies published
between January 2002 and April 2018 with ≥12 weeks follow-up between strongly anticholinergic drug exposure and the
study outcome measurement. We pooled adjusted odds ratios (OR) for studies reporting any, and at least short-term (90+
days) or long-term (365+ days) anticholinergic use for dementia and MCI outcomes, and standardised mean differences
(SMD) in global cognition test scores for cognitive decline outcomes. Statistical heterogeneity was measured using the I2
statistic and risk of bias using ROBINS-I.
Results: twenty-six studies (including 621,548 participants) met our inclusion criteria. ‘Any’ anticholinergic use was associated
with incident dementia (OR 1.20, 95% confidence interval [CI] 1.09–1.32, I2 = 86%). Short-term and long-term use were
also associated with incident dementia (OR 1.23, 95%CI 1.17–1.29, I2 = 2%; andOR 1.50, 95%CI 1.22–1.85, I2 = 90%).
‘Any’ anticholinergic use was associated with cognitive decline (SMD 0.15; 95% CI 0.09–0.21, I2 = 3%) but showed no
statistically significant difference for MCI (OR 1.24, 95% CI 0.97–1.59, I2 = 0%).
Conclusions: anticholinergic drug use is associated with increased dementia incidence and cognitive decline in observational
studies. However, a causal link cannot yet be inferred, as studies were observational with considerable risk of bias. Stronger
evidence from high-quality studies is needed to guide the management of long-term use.
Keywords: systematic review,meta-analysis, anticholinergics, dementia, cognition, older people
Key Points
• We synthesised evidence from 26 observational studies.
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• Anticholinergic drug use, particularly long-term use, is associated with greater incidence of dementia and cognitive decline.
• However, all but one study was at serious or critical risk of bias, and the findings were heterogeneous.
• The potential benefits and harms should be carefully considered when initiating and continuing anticholinergic drugs.
• Higher-quality studies are needed, targeting specific medication classes, and designed to reduce biases in previous studies.
Introduction
Dementia affects more than 40 million people with direct
healthcare costs of $818 billion in 2015 [1]. Dementia
is characterised by irreversible and progressive cognitive
impairment, with consequent disability and dependence.
‘Cognitive impairment’ itself refers to problems with
cognitive abilities such as memory, problem solving,
learning, perception and language. Cognitive impairments
are common in the older population, with different aspects
of cognition independently affected with age and by different
neurological diseases [2]. While cognitive impairment
does not always progress to dementia, it nevertheless
presents a social and economic cost. A classification of
‘mild cognitive impairment (MCI)’ identifies those with
cognitive impairments that are not severe enough to meet
the definition of dementia [3]. Many different operational
definitions of dementia, cognitive impairment and MCI are
used in clinical and research contexts.
Identification of possible modifiable risk factors for
dementia is paramount [4]. Some studies have suggested
that anticholinergic medication use might be a modifiable
risk factor for cognitive impairment or dementia [5, 6].
Drugs with anticholinergic properties inhibit the action
of acetylcholine at its receptor [7]. Such drugs have
many indications [7], including urinary incontinence and
depression [8]. Short-term cognitive impairments are well-
known side effects of anticholinergic drugs, but several recent
observational studies suggest links to longer-term cognitive
impairment and dementia incidence [9–11]. Around 10%
of people aged 65 years and older regularly use strongly
anticholinergic drugs [12, 13].
Several observational studies report an association
between anticholinergic drug use and cognitive function
[9,10,14,15]; however, the magnitude of effects and
strengths of their study designs vary considerably [16].
A review conducted by the members of our study team
identified 33 observational studies of cognitive effects of
anticholinergics, with 23 studies reporting lower cognitive
function among users [16]. However, this review did not
include a meta-analysis, nor specifically consider long-term
effects or risks of bias. A separate meta-analysis reported
an association between anticholinergic use and dementia
incidence but included only three cohort studies [17]. Larger
and more carefully controlled observational studies have
since been published addressing limitations of earlier work;
hence a new quantitative systematic review is warranted
[9,10].The evidence regarding these relationships arises from
non-randomised observational studies, which are subject to
uncontrolled confounding, misclassification and selection
bias. Hence a careful assessment of risk of bias is needed
when interpreting individual or pooled study findings.
Here we report a systematic review and meta-analysis of
the association between strongly anticholinergic drug use
and subsequent cognitive decline, incident dementia and
incident MCI, in older adults. We carefully assess risk of bias
and the reasons for any heterogeneity in study findings.
Methods
Registration
The study protocol was registered with PROSPERO (Reg-
istration:CRD42016039289). This systematic review and
meta-analysis was reported according to the Meta-analyses
of Observational Studies in Epidemiology guidelines [18].
Search strategy
An updated search from our 2014 review [16] was
undertaken by one researcher (YKL) using Ovid SP
MEDLINE and EMBASE between January 2013 and
March 2016 (search terms given in Appendix 1), using
recommended methods for updating searches [19]. Further
studies identified using this search were automatically
forwarded between March 2016 and April 2018. There
were no language restrictions. The previous review search
began in 2002 to capture studies using anticholinergic scales,
with studies published before 2002 generally using serum
anticholinergic activity (SAA) [20]. We also re-evaluated
all studies included in the previous review for inclusion
in the current review [16] and re-screened abstracts from
non-English and retrospective studies excluded from that
review. References in published systematic reviews were
hand searched, and we contacted experts within the field
for further eligible studies.
Selection criteria
Abstracts were independently assessed for inclusion by two
researchers (NP and WYC or CH). Inclusion criteria were
randomised controlled trials (RCTs) or observational studies
investigating anticholinergic effects on human adults (using
an anticholinergic scale [8, 21, 22] or specific anticholinergic
drugs), on the following outcomes: (i) dementia, (ii) MCI or
(iii) cognitive decline.
Exclusion criteria were <12 weeks follow-up between
measurement of drug exposure and outcome; cross-sectional
studies, case reports, literature reviews, clinical audits, edi-
torials and conference abstracts; mean participant age less
than 50 years; anticholinergic exposure based on SSA alone
(due to inconsistent relationships with cognitive outcomes
[23]); and studies includingmostly participants with existing
dementia.
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Data extraction
The following were independently extracted by two researchers
(NP and WYC or CH): study design, data source, country,
proportion of male participants, mean participant age,
number of participants, definition of anticholinergic drug,
primary exposure measure, length of follow-up time, effects
on cognitive outcomes (as odds ratios [OR], hazard ratios or
raw data that could be converted into an OR) and covariates
included in multivariable analysis. Authors were contacted
for additional data when studies provided insufficient data
for calculating an OR. The extracted information was
reviewed by two statisticians (KR and CG) and discrepancies
resolved by consensus.
Risk of bias assessment
Risk of bias with respect to estimating causal effects
was independently assessed for each study effect by two
researchers (WYC and NP) using the Cochrane Risk Of Bias
In Non-randomized Studies—of Interventions (ROBINS-I)
tool [24]. Discrepancies were resolved through consensus.
Data synthesis
Results were pooled using random-effects meta-analysis and
the inverse variance method where studies used similar def-
initions of both drug exposure and outcome. Findings for
dementia or MCI outcomes were pooled separately. The
relative risk was assumed to approximate the OR as dementia
and MCI were sufficiently rare events. ORs were pooled
separately for studies reporting any (≥1 day), at least short-
term (≥90 days) and long-term (≥365 days, or at baseline
and 1- or 2-year follow-up for studies using patient inter-
views) anticholinergic use. Only the effects of drugs with
definite/strong anticholinergic activity (scores 2 or 3 on the
ACB scale or an equivalent definition) were included. Many
drugs are considered to have mild anticholinergic activity
(scored 1 on anticholinergic scales), i.e. serum anticholiner-
gic activity or in vitro affinity to muscarinic receptors, but no
known clinically relevant cognitive effects, and are excluded
from this review. Some studies estimate the ‘anticholinergic
load’ by summing the individual anticholinergic scale scores
for each drug participants are taking; however, there were
too few studies reporting these associations to include in the
meta-analysis.
For each study that reported decline in global cogni-
tion measured as a continuous outcome, we derived the
standardised mean difference (SMD). This was estimated
as the mean difference in decline between exposed and
non-exposed groups, divided by the standard deviation of
the change scores. For studies that only reported an OR
for decline following dichotomisation of change scores, we
assumed that cognitive decline was normally distributed and
converted this to the SMD by dividing the log-odds ratio
by 1.81 [25]. Estimated SMDs were then pooled using the
random-effects inverse variance method.
We measured statistical heterogeneity using the I 2 statis-
tic. The following sources of heterogeneity were assessed
using random-effects meta-regression: mean participant age,
proportion female, mean baseline Mini-Mental State Exam-
ination (MMSE) score (where recorded), study follow-up
time, population type (community versus care home) and
patient disease group (general, specific condition). We report
subgroup results for characteristics associated with the effect
estimate at P < 0.10. We also performed three post hoc
sensitivity analyses: first excluding studies with a critical risk
of bias, second excluding studies only examining a single
drug class and third including only studies using the ACB
scale [8], as the most common scale used aimed at central
anticholinergic effects. Data was analysed using Stata version
14.0 (StataCorp, College Station, TX).
Results
Study selection
We screened 521 study abstracts: 347 identified through
the new literature search, 46 from the previous review, 42
retrospective studies, 74 non-English studies excluded from
the previous review and 12 via other sources (Appendix
Figure 1). Full text was extracted for 79 studies, with
26 studies meeting our inclusion criteria; 23 cohort
studies [10,11,14,15,26–44]; and three case-control studies
[9,45,46]. Nineteen studies are included in the meta-
analyses.
Demographics
The 26 identified studies included 621,548 participants with
mean study duration of 73 months (range 3–241 months,
Table 1, Appendix Tables 1 and 2). Studies were conducted
in Europe, North America or Taiwan and were mainly
community based, except for three studies of outpatients and
two studies of care home residents. The mean proportion of
female participants was 60%, and mean participant age was
74 years (range 52–86 years).
Drug use was assessed by patient interview, self-reported
written survey and review of prescriptions and drug con-
tainers or directly from insurance claims, pharmacy or pri-
mary care records. Studies varied according to how they
classified anticholinergic drug exposure: 14 studies used a
published anticholinergic rating scale (ACB or ADS), four
used a literature review and/or expert panel analysis, one
used their own validated clinician-rated scale and two studies
used national drug/therapeutic formulary classifications.The
scales generally aimed to examine central anticholinergic
effects, but some were more likely to also capture peripheral
effects (Appendix Table 1). One study specifically tested
selective serotonin reuptake inhibitors (SSRIs) only and three
examined bladder anticholinergics only.
Risk of bias
Findings from six studies were rated as having a critical risk
of bias, 19 as serious, one as moderate and none as low
(Appendix Tables 3 and 4). Of the risk of bias subsections: 14
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Table 1. Design and characteristics of included studies
Study Study design, data source,
country
Setting and population Number of
participants
Mean age (years), %
male
Study duration
(months)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ancelin 2006 Cohort, Eugeria longitudinal
study of cognitive decline,
France
Community 327 66, NS 12 and 96
Bali 2015 Cohort, Medicare health
insurance data, USA
Nursing home,
residents with
depression
23,748 NS, 28 24
Boustani 2007 Cohort, surveyed African
Americans identified by
residential addresses, USA
Community 1,558 78, 34 60
Cai 2013 Cohort, Indianapolis Dementia
Screening and Diagnosis study,
USA
Community 3,413 72, 29 12
Campbell 2010 Cohort, Indianapolis Ibadan
Dementia Project, USA
Community 1,652 82, 31 72
Campbell 2018 Cohort, Indiana Network for
Patient Care, USA
Community 350 71, 21 48
Carriere 2009 Cohort, The 3 City Study,
France
Community 6,463 74, 40 48
Chatterjee 2016 Case-control, Medicare health
insurance data, USA
Community 141,940 80, 19 36
Chuang 2017 Cohort, Baltimore Longitudinal
Study of Aging, USA
Community 723 52, 69 241a
Esin 2015 Cohort study, Geriatric medicine
outpatient clinic, Turkey
Outpatients, overactive
bladder patients
168 74, 8 3
Fox 2011 Cohort, MRC-CFAS, UK Community and
institutions
8,334 75, 40 24
Gomm 2016 Cohort, AgeCoDe study,
Germany
Community 73,679 83, 24 84
Gray 2015 Cohort, Adult Changes in
Thought Study, USA
Community, patients
with health insurance
797 74b, 40 120
Grossi 2019 Cohort, MRC-CFAS, UK Community and
institutions
3,045 75, 40 96
Han 2008 Cohort, Connecticut Veterans
Longitudinal Cohort, USA
Community 544 74, 100 24
Kashyap 2014 Cohort, Outpatient clinics in
Quebec, Canada
Outpatient, urinary
incontinence patients
102 72, 16 12
Koyama 2013 Cohort, Study of Osteoporotic
Fractures, USA
Community 1,429 83, 0 60
Moga 2017 Case-control, National
Alzheimer’s Co-ordinating
Center cohort, USA
Community 7,735 77, 42 15a
Papenberg 2017 Cohort, SNAC-K, Sweden Community 1,473 70, 39 72
Richardson 2018 Case-control, Clinical Practice
Research Datalink, UK
Community 324,703 71, 37 240
Saczynski 2015 Cohort, Health and Retirement
Study and Prescription Data
Study, USA
Community 3,714 72, 37 72
Shah 2013 Cohort, Religious Orders Study,
USA
Community, Catholic
clergy
896 75, 31 216
Whalley 2012 Cohort, 1932 Scottish Mental
Survey, Scotland
Community 210 77, 58 120
Wu 2017 Cohort, The Longitudinal Older
Veterans Study, Taiwan
Veterans care homes 274 86, 100 6
Yang 2017 Cohort, Taiwan National Health
Insurance Research Data set,
Taiwan
Community 10,160 62, 64 132
Yarnall 2015 Cohort, ICICLE-PD, UK Community and
outpatients
195 69, 58 18
aMean number of months. bMedian age. Abbreviations: AgeCoDe =German Study on Aging, Cognition and Dementia in Primary Care Patients, ICICLE-
PD= Incidence of Cognitive Impairment in Cohorts with Longitudinal Evaluation—Parkinson’s Disease, MRC-CFAS =Medical Research Council Cognitive
Function and Ageing Studies, NS = not stated, SNAC-K = Swedish National Study on Aging and Care in Kungsholmen.
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(54%) had a serious or critical risk of bias for confounding;
23 (88%) had a serious risk of bias for participant selection;
and 10 (40%) had a serious risk of bias for missing data.
Althoughmany studies controlled for age, sex and education,
few accounted for anticholinergic drug indications such as
depression (Appendix Table 2). However, 24 (92%) had a
low risk of bias for outcomemeasurement, and 23 (88%) had
a low or moderate risk of bias for selection of the reported
result.
Anticholinergics and dementia
Eleven of the 12 studies reporting dementia as an outcome
were included in the quantitative analyses. The pooled OR
for any use of drugs with definite anticholinergic activity
and incident dementia was 1.20 (95% confidence interval
[CI] 1.09–1.32) from seven studies (Figure 1). There was
substantial heterogeneity (I 2 = 86%); however, this is likely
influenced by the inclusion of three large studies with small
variances [47]. No study-level characteristics examined using
meta-regression were significantly associated with theOR for
dementia. Three large studies dominated the analysis and
were similarly derived from US and UK population-based
electronic health records [9,10,45]. All had good confound-
ing control: two studies adjusted for a wide range of con-
founders [9,10], and the other restricted to the main indica-
tion of depression [45]. The pooled OR for anticholinergic
use for ≥90 days and ≥365 days and dementia were 1.23
(95% CI 1.17–1.29) and 1.50 (95% CI 1.22–1.85) from
three and six studies, respectively (Figure 1). There was little
heterogeneity (I 2 = 2%) for ≥90 days use, but substantial
heterogeneity for ≥365 days use (I 2 = 90%). One further
cohort study reported no association between anticholinergic
use and dementia, reporting an OR of 0.67 (95% CI 0.40–
1.15) [39]. However, the definition of anticholinergics was
broad, being dominated by drugs with ‘mild’ anticholinergic
activity, and so findings were not comparable with the other
studies.
Anticholinergics and MCI
Six cohort studies estimated the effect of drugs with definite
anticholinergic activity and incidentMCI.Three studies esti-
mated the effect of any definite anticholinergic use (pooled
OR 1.24; 95% CI 0.97–1.59; I 2 = 0%) (Figure 2). One
study reported an OR of 1.70 (95% CI 0.52–5.57) for
≥60 days use [26], and we estimated a pooled OR of 2.52
(95% CI 0.71–8.95) from two studies examining long-
term use, albeit with substantial heterogeneity (I 2 = 80%). A
further study reported an OR of 1.15 (95% CI 1.01–1.31)
per year of standardised daily doses and incident MCI and
hence could not be numerically combined with the other
exposure classifications [43]. For a further cohort study of
Parkinson’s disease patients, we estimated an unadjusted OR
of 1.17 (95% CI 0.66–2.06) between anticholinergic use
including mild anticholinergics and MCI [42].
Anticholinergics and cognitive decline
Cognitive decline was reported on by 14 studies. We cal-
culated the SMD of global cognitive decline for six studies
[11,14,31,36,38,46]: five studies reportedMMSE, while one
calculated a composite score from 19 cognitive tests [38]. All
but one study adjusted for some potential confounders [31].
Greater cognitive decline was consistently observed among
patients taking anticholinergic drugs (SMD 0.15; 95% CI
0.09–0.21, I 2 = 3%) (Figure 3). There was some evidence
that studies with longer follow-up reported greater cognitive
decline (P = 0.08 from meta-regression) (Appendix Figure
2).
A further seven cohort studies were excluded from the
meta-analysis. Two studies reported cognition at follow-up
and not decline since baseline [27,35]. The Scottish Mental
Survey of 1932 provided insufficient detail for pooling, but
reported lower mean MMSE scores with anticholinergic use
[39]. Finally, four studies used incompatible definitions of
anticholinergic use. We were able to calculate SMDs in
MMSE scores with anticholinergic use of 0.26 (95% CI
−0.02, 0.55) over 18-month follow-up and 0.55 (95% CI
0.17, 0.92) over 6-month follow-up within a Parkinson’s
disease study and Taiwan Veterans care home study, respec-
tively [40,42]. However, both studies included drugs with
mild anticholinergic activity. The SMD in the decline in the
Health and Retirement Study (HRS) 27-point Cognition
Measure was 0.02 (95% CI −0.08, 0.12) over a 6-year
follow-up for a total anticholinergic load of ≥3 in US HRS
study [37]. A Canadian cohort study of urinary incontinence
clinic outpatients reported no significant decline in MMSE
with increased total anticholinergic load, but provided insuf-
ficient data for pooling [26].
Sensitivity analyses
None of the sensitivity analyses had a substantial effect on
the pooled estimates (Appendix Figures 3–11).
Updated search
Further automated study searches between April 2018 and
November 2019 identified eight additional studies meeting
our inclusion criteria [48–55]. Two studies focussed on
depression [48, 49], and one on Parkinson’s disease [50],
with the others having no specific disease focus. Five studies
would be excluded from meta-analysis due to incompati-
ble definitions of anticholinergic exposure, cognition or by
patient duplication [48–52]. Using ROBINS-I, all study
estimates were at serious/critical risk of bias and consistent
with our review [24]. One large study replicated findings
from the UK primary care population [9], in another UK
primary care cohort [55], confirming that associations with
dementia are limited to certain classes of anticholinergic
medications. Similarly, a cohort study from the Netherlands
reported greater dementia incidence with a higher anti-
cholinergic burden score, but not once excluding antipsy-
chotics and antidepressants [51].
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Figure 1. Meta-analysis of odds ratios for dementia by any, at least short-term and long-term definite anticholinergic use versus
no use. ∧OR (95% CI) estimated as the inverse variance weighted average of the published adjusted ORs for exposures of 1–90,
91–365, 366–1095 and>1095 daily doses for any use, of 91–365, 366–1095 and>1095 daily doses for short-term use (90+ days)
and of 366–1095 and>1095 daily doses for long-term use (365+ days). ‡OR (95% CI) estimated as the inverse variance weighted
average of the published adjusted ORs for exposures of 90–364, 365–1459 and >1460 daily doses for short-term use (90+ days)
and of 365–1459 and >1460 daily doses for long-term use (365+ days). ∗The Cai 2013 estimate is for 60+ days use versus <60
days, Ancelin 2006 estimated long-term use (365+ days) as use at baseline and at 1-year follow-up and Gomm 2016 estimated
long-term use (365+ days) as a prescription every quarter for 6 consecutive quarters. ∗∗OR (95% CI) estimated as the inverse
variance weighted average of the published adjusted ORs for exposures of oxybutynin, solifenacin and tolterodine. Abbreviations:
n, number of dementia cases; N , number of participants.
Discussion
Observational studies report, on average, a 20% greater
incidence of dementia associated with the use of drugs with
definite anticholinergic activity. Greater associations with
dementia are also reported with longer durations of exposure.
Observational studies also report anticholinergic drug use is
associated with long-term global cognitive decline. However,
there was no randomised evidence, study findings are hetero-
geneous and all but one study had a serious or critical risk
of bias. No reported factor could explain the heterogeneous
study findings.
To our knowledge, this is the most comprehensive sys-
tematic review and meta-analysis on the long-term cognitive
effects associated with anticholinergic drug use. We excluded
cross-sectional studies and studies with insufficient follow-
up. We used recognised methods for performing an updated
search [19] and minimised the risk of missing studies. We
provided a thorough assessment of risk of bias by utilising
the latest rating scales. The included studies used different
scales to measure anticholinergic burden, and although they
differ in how they classify anticholinergic burden, they are
typically consistent in which drugs they classify as strongly
or definitely anticholinergic [56].
A major limitation in drawing substantive conclusions
from this review is that all studies were observational and
most were rated at serious/critical risk of bias [24]. In particu-
lar, 88% included participants who began taking anticholin-
ergic drugs before the study period. As such, the ROBINS-I
tool rates these study estimates at serious risk of selection
bias [24] and therefore a serious overall risk of bias at best.
For short-term effects, examining only new users of therapy
reduces biases by capturing early events and confounders for
prescribing therapy [57]. However the impact of excluding
prevalent users on selection bias when examining long-term
effects is unclear [58]. The largest threat to study validity
is likely residual confounding, given that anticholinergics
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Figure 2. Meta-analysis of odds ratios for mild cognitive impairment by any, at least short-term and long-term definite
anticholinergic use versus no use. ∗Campbell 2010 estimated long-term use (365+ days) as use at all participating waves (baseline,
3-year and 6-year follow-up).
are indicated for conditions also associated with cognitive
decline such as depression and Parkinson’s disease [59–61].
There may also be residual confounding by frailty, as only
one study explicitly adjusted for frailty [40]. Definitions
of incident dementia and MCI were generally consistent.
Studies varied, however, on how they assessed and reported
cognitive function; therefore we could only pool results from
six studies. There was moderate risk of exposure misclassifi-
cation, particularly for studies relying on self-reported use
or prescription records. Self-reported use of anticholinergic
drug classes has only moderate agreement with pharmacy
dispensing records [62]. Publication bias is possible, but
difficult to assess owing to the lack of registration require-
ments for observational studies. Unfortunately, we were
unable to pool absolute risks, as only one study provided
these [9].
Our findings concur with previous reviews. A previ-
ous meta-analysis reported a stronger association between
anticholinergic use and incident dementia (OR 1.43; 95%
CI 1.16–1.73) but only pooled results from three cohort
studies [17]. Whether the observed associations between
anticholinergic drug use and dementia is a causal relationship
or reflects risk factors or early symptoms of dementia (such
as depression or bladder instability) remains unclear from
the available evidence. Some studies reported an increasing
dementia risk with greater exposure to anticholinergic drugs,
consistent with a causal link [9,10,26]. However, few studies
excluded drug exposure in the period just prior to dementia
[9,10,41], and so drugs may have been prescribed for early
symptoms of dementia. Two large UK studies report dif-
ferences in dementia risk according to anticholinergic drug
class, inconsistent with a causal link [9,55].
Mechanistic evidence is limited, although some neu-
ropathological studies in humans and mice support a role
of anticholinergics in affecting neurodegenerative pathology
[63], and anticholinergic use has been associated with
increased brain atrophy and reduced glucose metabolism
[64]. Evidence from RCTs on anticholinergic cessation
has failed to show improvements in cognition, but has
generally been underpowered and has focussed on short-term
outcomes [65].
This study adds to the weight of evidence supporting
current recommendations that prescribers should be cau-
tious about using medications with anticholinergic activity
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Figure 3. Meta-analysis of standardised mean differences in global cognitive decline by any definite anticholinergic use versus no
use. ∗Standardised mean difference (95% CI) estimated as the inverse variance weighted average of the estimated standardised mean
difference for prevalent and incident users. Decline in global cognition was defined as the change in mean z-score across 19 cognitive
tests. Abbreviations: d , standardised mean difference.
in older people. Prescribers should discuss the risks and
benefits of anticholinergic drugs with patients and their
carers and consider either avoiding medication or using
alternatives where appropriate [66]. However, the current
evidence is insufficient to warrant aggressive deprescribing of
these drugs due to long-term cognitive effects. Nevertheless,
other known effects such as dry mouth and eyes, confusion,
constipation and urinary retention remain a concern [58,
59]. Due to our findings of stronger associations with long-
term use, clinicians should regularly review and consider
stopping anticholinergic drugs if there is no clear evidence
of benefit. There is a need for consensus on the management
of the long-term use of anticholinergic drugs, particularly on
developing clear timeframes regarding proposed durations of
use.
The decision to prescribe anticholinergic drugs needs
careful weighing up of the risks and benefits, and this review
highlights the lack of reliable research evidence on cognitive
risks.
Although such evidence will be difficult to obtain, we
offer suggestions in Appendix 3. There is also a need to
regularly update anticholinergic assessment tools and agree
consensus on their ratings. Due to the growing number of
assessment tools, we recommend a systematic harmonisation
of current tools specifically aimed at examining central anti-
cholinergic effects, taking into consideration blood–brain
barrier permeability, to facilitate care and research [67].
Supplementary Data: Supplementary data mentioned in
the text are available to subscribers in Age and Ageing online.
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